CSIMarket
 


Nuvation Bio Inc   (NUVB)
Other Ticker:  
 

Nuvation Bio Inc 's Quick Ratio

NUVB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 38.37 below Nuvation Bio Inc average.

Within Major Pharmaceutical Preparations industry 4 other companies have achieved higher Quick Ratio than Nuvation Bio Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the III Quarter 2023 to 48, from total ranking in the second quarter 2023 at 55.

Explain Quick Ratio?
How much Cash & cash equivalents NUVBīs has?
What are NUVBīs Current Liabilities?


NUVB Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 15.22 % -36.95 % -41.46 % -22.24 % 5.28 %
Y / Y Cash & cash equivalent Change -8.1 % -10.36 % -12.35 % -13.64 % -14.88 %
Quick Ratio MRQ 38.37 47.04 51.52 50.23 48.1
NUVB's Total Ranking # 48 # 55 # 12 # 41 # 83
Seq. Current Liabilities Change 20.35 % 6.87 % -4.63 % -6.07 % -34.14 %
Seq. Cash & cash equivalent Change -1.83 % -2.43 % -2.18 % -1.92 % -4.24 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 5
Healthcare Sector # 7
Overall Market # 48


Quick Ratio Statistics
High Average Low
82.58 47.53 0.34
(Mar 31 2021)   (Dec 31 2020)




Financial Statements
Nuvation Bio Inc 's Current Liabilities $ 16 Millions Visit NUVB's Balance sheet
Nuvation Bio Inc 's Cash & cash equivalent $ 619 Millions Visit NUVB's Balance sheet
Source of NUVB's Sales Visit NUVB's Sales by Geography


Cumulative Nuvation Bio Inc 's Quick Ratio

NUVB's Quick Ratio for the trailling 12 Months

NUVB Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 15.22 % -36.95 % -41.46 % -22.24 % 5.28 %
Y / Y Cash & cash equivalent TTM Growth -8.1 % -10.36 % -12.35 % -13.64 % -14.88 %
Quick Ratio TTM 46.28 49.17 44.02 39.73 39.11
Total Ranking TTM # 2031 # 2066 # 2261 # 2393 # 32
Seq. Current Liabilities TTM Growth 20.35 % 6.87 % -4.63 % -6.07 % -34.14 %
Seq. Cash & cash equivalent TTM Growth -1.83 % -2.43 % -2.18 % -1.92 % -4.24 %


On the trailing twelve months basis Due to growth in Current Liabilities in the III Quarter 2023 to $16.14 millions, cumulative Quick Ratio decreased to 46.28 below the Nuvation Bio Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 425 other companies have achieved higher Quick Ratio than Nuvation Bio Inc . While Quick Ratio overall ranking has improved so far to 2031, from total ranking during the twelve months ending second quarter 2023 at 2066.

Explain Quick Ratio?
How much Cash & cash equivalents NUVBīs has?
What are NUVBīs Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 426
Healthcare Sector # 815
Within the Market # 2031


trailing twelve months Quick Ratio Statistics
High Average Low
66.99 47.53 19.26
(Sep 30 2021)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Moonlake Immunotherapeutics  48.12 $ 495.979  Millions$ 10.308  Millions
Third Harmonic Bio Inc   46.52 $ 273.892  Millions$ 5.888  Millions
Altimmune inc   46.22 $ 140.779  Millions$ 3.046  Millions
Essa Pharma inc   43.36 $ 148.076  Millions$ 3.415  Millions
Nuvation Bio Inc   38.37 $ 619.339  Millions$ 16.143  Millions
Merrimack Pharmaceuticals Inc  38.34 $ 18.904  Millions$ 0.493  Millions
Xbiotech Inc   38.19 $ 202.191  Millions$ 5.294  Millions
Morphic Holding inc   37.57 $ 725.067  Millions$ 19.298  Millions
Eliem Therapeutics Inc   37.03 $ 107.433  Millions$ 2.901  Millions
Royalty Pharma Plc  35.91 $ 941.748  Millions$ 26.222  Millions
Rayzebio Inc   34.09 $ 540.169  Millions$ 15.847  Millions
Cymabay Therapeutics Inc   31.72 $ 438.778  Millions$ 13.831  Millions
Atea Pharmaceuticals Inc   31.50 $ 595.126  Millions$ 18.893  Millions
Greenwich Lifesciences Inc   30.76 $ 9.144  Millions$ 0.297  Millions
Verona Pharma Plc  29.80 $ 257.366  Millions$ 8.636  Millions
Aprea Therapeutics Inc   29.39 $ 25.354  Millions$ 0.863  Millions
Theseus Pharmaceuticals Inc   29.29 $ 205.122  Millions$ 7.003  Millions
Viking Therapeutics Inc   28.75 $ 376.241  Millions$ 13.086  Millions
Karuna Therapeutics Inc   27.40 $ 1,341.510  Millions$ 48.968  Millions
Atossa Therapeutics Inc   27.33 $ 94.141  Millions$ 3.444  Millions
Disc Medicine Inc   25.70 $ 370.541  Millions$ 14.416  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.17 $ 349.712  Millions$ 14.471  Millions
Bright Minds Biosciences Inc   24.16 $ 5.197  Millions$ 0.215  Millions
Design Therapeutics Inc   23.48 $ 290.940  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.08 $ 5.106  Millions$ 0.221  Millions
Diamedica Therapeutics Inc   22.23 $ 46.465  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.06 $ 266.600  Millions$ 12.087  Millions
Cyteir Therapeutics Inc   21.65 $ 129.242  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.64 $ 241.902  Millions$ 11.180  Millions

Date modified: 2023-11-03T16:02:10+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com